Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Lankes, Katharina ^a   Hundorfean, Gheorghe ^a   Harrer, Thomas ^a   Pommer, Ansgar J ^a   Agaimy, Abbas ^a   Angelovska, Irena ^a   Tajmir Riahi, Azadeh ^a   Göhl, Jonas ^a   Schuler, Gerold ^a   Neurath, Markus F ^a   Hohenberger, Werner ^a   Heinzerling, Lucie ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Autoimmune colitis; CMV; immune related adverse event irAE; immunotherapy; ipilimumab; multi epitope ligand cartography MELC; nivolumab; side effect management; virus reactivation

Indexed keywords

AMYLASE; CD20 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CIPROFLOXACIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; IPILIMUMAB; MESALAZINE; METRONIDAZOLE; NIVOLUMAB; PREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR INHIBITOR; VALGANCICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CASE REPORT; COLITIS; COLON BIOPSY; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FECES ANALYSIS; FEVER; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GENE EXPRESSION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MALE; METASTATIC MELANOMA; MOLECULAR IMAGING; MULTI EPITOPE LIGAND CARTOGRAPHY; PARENTERAL NUTRITION; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; SIGMOIDOSCOPY; VOMITING;

EID: 84973140928     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1128611     Document Type: Article

References (33)

1. A.K.Salama, F.S.Hodi. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011; 17(14):4622-8; PMID:21467163; 10.1158/1078-0432.CCR-10-2232
2. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; 10.1056/NEJMoa1003466
3. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, J.Weber, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26):2517-26; PMID:21639810; 10.1056/NEJMoa1104621
4. Z.Hanaizi, B.van Zwieten-Boot, G.Calvo, A.S.Lopez, M.van Dartel, J.Camarero, E.Abadie, F.Pignatti. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48(2):237-42; PMID:22030452; 10.1016/j.ejca.2011.09.018
5. D.Berman, S.M.Parker, J.Siegel, S.D.Chasalow, J.Weber, S.Galbraith, S.R.Targan, H.L.Wang. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11; PMID:21090563
6. K.A.Mitchell, H.Kluger, M.Sznol, D.J.Hartman. Ipilimumab-induced perforating colitis. J Clin Gastroenterol 2013; 47(9):781-5; PMID:23632354; 10.1097/MCG.0b013e31828f1d51
7. M.Slingerland, J.W.Nortier, R.A.Veenendaal, E.Kapiteijn. Severe colitis while responding to ipilimumab in metastatic melanoma. Acta Oncol 2012; 51(6):805-7; PMID:22551308; 10.3109/0284186X.2012.682630
8. K.E.Beck, J.A.Blansfield, K.Q.Tran, A.L.Feldman, M.S.Hughes, R.E.Royal, U.S.Kammula, S.L.Topalian, R.M.Sherry, D.Kleiner Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24(15):2283-9; PMID:16710025; 10.1200/JCO.2005.04.5716
9. C.J.Voskens, S.M.Goldinger, C.Loquai, C.Robert, K.C.Kaehler, C.Berking, T.Bergmann, C.L.Bockmeyer, T.Eigentler, M.Fluck The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8(1): e53745; PMID:23341990; 10.1371/journal.pone.0053745
10. R.L.Johnston, J.Lutzky, A.Chodhry, J.S.Barkin. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54(11):2538-40; PMID:19104936; 10.1007/s10620-008-0641-z
11. P.Attia, G.Q.Phan, A.V.Maker, M.R.Robinson, M.M.Quezado, J.C.Yang, R.M.Sherry, S.L.Topalian, U.S.Kammula, R.E.Royal Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23(25):6043-53; PMID:16087944; 10.1200/JCO.2005.06.205
12. J.Lutzky, J.Wolchok, O.Hamid, C.Lebbe, H.Pehamberger, G.Linette, V.de Pril, R.Ibrahim, A.Hoos, S.O'Dayet Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 27:15s, 2009 (suppl; abstr 9034); http://meetinglibrary.asco.org/content/34815-65
13. S.G.Downey, J.A.Klapper, F.O.Smith, J.C.Yang, R.M.Sherry, R.E.Royal, U.S.Kammula, M.S.Hughes, T.E.Allen, C.L.Levy Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13(22 Pt 1):6681-8; PMID:17982122; 10.1158/1078-0432.CCR-07-0187
14. O.Hamid, R.D.Carvajal. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 2013; 13(6):847-61; PMID:23421934; 10.1517/14712598.2013.770836
15. J.D.Wolchok, H.Kluger, M.K.Callahan, M.A.Postow, N.A.Rizvi, A.M.Lesokhin, N.H.Segal, C.E.Ariyan, R.A.Gordon, K.Reed Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369(2):122-33; PMID:23724867; 10.1056/NEJMoa1302369
16. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; 10.1056/NEJMoa1504030
17. J.S.Weber, K.C.Kähler, A.Hauschild. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21):2691-7; PMID:22614989; 10.1200/JCO.2012.41.6750
18. J.Naidoo, D.B.Page, B.T.Li, L.C.Connell, K.Schindler, M.E.Lacouture, M.A.Postow, J.D.Wolchok. Toxicities of the Anti-PD-1 and Anti-PD-L1 Immune Checkpoint Antibodies. Ann Oncol pii: mdv383. [Epub ahead of print] Review 2015; 26(12):2375-91; 10.1093/annonc/mdv383
19. C.Ostalecki, A.Konrad, E.Thurau, G.Schuler, R.S.Croner, A.J.Pommer, M.ael Stürzl. Combined multi-gene analysis at the RNA and protein levels in single FFPE tissue sections. Exp Mol Pathol 2013; 95(1):1-6; PMID:23583336; 10.1016/j.yexmp.2013.03.008
20. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369(2):134-44; PMID:23724846; 10.1056/NEJMoa1305133
21. J.D.Lord, R.C.Hackman, A.Moklebust, J.A.Thompson, C.S.Higano, D.Chielens, G.Steinbach, G.B.McDonald. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2010; 55(5):1396-405; PMID:19507029; 10.1007/s10620-009-0839-8
22. M.L.Yeong, P.B.Bethwaite, J.Prasad, W.H.Isbister. Lymphoid follicular hyperplasia–a distinctive feature of diversion colitis. Histopathology 1991; 19(1):55-61; PMID:1916687; 10.1111/j.1365-2559.1991.tb00894.x
23. C.M.Edwards, B.George, B.F.Warren. Diversion colitis: new light through old windows. Histopathology 1999; 35(1):86-7; PMID:10383813; 10.1046/j.1365-2559.1999.0728b.x
24. S.R.Ell, P.H.Frank. Spectrum of lymphoid hyperplasia: colonic manifestations of sarcoidosis, infectious mononucleosis, and Crohn's disease. Gastrointest Radiol 1981; 6(4):329-32; PMID:7308713; 10.1007/BF01890279
25. M.M.Yeung, S.Melgar, V.Baranov, A.Oberg, A.Danielsson, S.Hammarström, M.L.Hammarström. Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-gammadelta expression. Gut 2000; 47(2):215-27; PMID:10896913; 10.1136/gut.47.2.215
26. N.Iida, A.Dzutsev, C.A.Stewart, L.Smith, N.Bouladoux, R.A.Weingarten, D.A.Molina, R.Salcedo, T.Back, S.Cramer Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342(6161):967-70; PMID:24264989; 10.1126/science.1240527
27. L.Zitvogel, L.Galluzzi, S.Viaud, M.Vétizou, R.Daillère, M.Merad, G.Kroemer. Cancer and the gut microbiota: an unexpected link. Sci Transl Med 2015; 7(271):271 PMID:25609166; 10.1126/scitranslmed.3010473
28. O.Yazici, M.A.Sendur, S.Aksoy. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20(22):6716-6724; PMID:24944464; 10.3748/wjg.v20.i22.6716
29. S.Minter, I.Willner, K.Shirai. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 2013; 31(19):e307-8; PMID:23690418; 10.1200/JCO.2012.46.5831
30. V.Cecchinato, E.Tryniszewska, Z.M.Ma, M.Vaccari, A.Boasso, W.P.Tsai, C.Petrovas, D.Fuchs, J.M.Heraud, D.Venzon Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008; 180(8):5439-47; PMID:18390726; 10.4049/jimmunol.180.8.5439
31. F.Wightman, A.Solomon, S.S.Kumar, N.Urriola, K.Gallagher, B.Hiener, S.Palmer, C.Mcneil, R.Garsia, S.R.Lewin. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS 2015; 29(4):504-6; PMID:25628259; 10.1097/QAD.0000000000000562
32. U.Uslu, A.Agaimy, G.Hundorfean, T.Harrer, G.Schuler, L.Heinzerling. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J Immunother 2015; 38(5):212-5; PMID:25962110; 10.1097/CJI.0000000000000081
33. L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, MI Schmidgen, R Gutzmer, JS Utikal, D Göppner, JC Hassel, F Meier, J Tietze, I Thomas, C Weishaupt, M Leverkus, R Wahl, U Dietrich, C Garbe, MC Kirchberger, T Eigentler, C Berking, A Gesierich, AM Krackhardt, D Schadendorf, G Schuler, R Dummer, LM Heinzerling. Cutaneous, gastrointestinal, hepatic, endocrine and renal side effects of anti-PD-1 therapy. Eur J Cancer (in press); 10.1016/j.ejca.2016.02.025